BREAKTHROUGH CANCER PAIN (BTCP) · White paper
Breakthrough Cancer Pain Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About breakthrough cancer pain — and why its trials are hard
Breakthrough cancer pain (BTcP) is a transient, severe flare of pain that erupts despite well-controlled baseline analgesia, typically peaking within minutes and lasting from a quarter-hour to about an hour. It affects an estimated 40-80% of cancer patients with baseline pain and is now formally recognized in ICD-11 (MG30.1), reflecting its distinct pathophysiology and need for rapid-onset therapy. The pharmacologic answer has centered on transmucosal immediate-release fentanyl (TIRF) products designed for fast relief in opioid-tolerant patients, supported by a restricted TIRF REMS program. Notably, as of 2024 manufacturers voluntarily discontinued all TIRF products, leaving immediate-release morphine, oxycodone, hydromorphone, methadone, and transdermal fentanyl as the mainstays. Trials are complicated by episode heterogeneity, the rapid and short course of attacks, subjective pain reporting, and opioid tolerance. Endpoints emphasize speed and magnitude of pain-intensity reduction, using summed pain intensity difference (SPID) and pain relief scales at early time points, plus onset, duration of relief, and side-effect burden. Emerging directions include inhaled fentanyl, cannabinoids, and neuromodulation.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Fentanyl oral transmucosal lozenge (Actiq) | 1998 | Opioid-tolerant adults with BTcP (voluntarily withdrawn ~2024) | NCT00222361; pivotal titration/crossover trials | Pain relief scores vs placebo | Significant pain relief at 15-60 min; ~75% achieved a successful dose |
| Fentanyl buccal tablet (Fentora) | 2006 | Opioid-tolerant adults with BTcP (withdrawn ~2024) | NCT00433776 | SPID30 vs placebo | SPID30 3.0 vs placebo 1.8; significant at all measured time points |
| Fentanyl buccal soluble film (Onsolis) | 2009 | Opioid-tolerant adults with BTcP (withdrawn ~2024) | Pivotal SPID-based BTcP trial | Pain intensity difference vs placebo | Statistically significant pain reduction vs placebo (unverified exact value) |
| Fentanyl sublingual tablet (Abstral) | 2011 | Opioid-tolerant adults with BTcP (withdrawn ~2024) | NCT00423117 | SPID30 vs placebo | Significant SPID30 improvement; ~60% titrated to a successful dose |
| Fentanyl nasal spray (Lazanda) | 2011 | Opioid-tolerant adults with BTcP (withdrawn ~2024) | NCT00855454 | SPID30 / PID vs placebo | Significant reduction in pain intensity at 30 min and all time points |
| Fentanyl sublingual spray (Subsys) | 2012 | Opioid-tolerant adults with BTcP (withdrawn ~2024) | NCT01498664 | SPID30 vs placebo | Significant pain reduction vs placebo from 5 min onward |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in breakthrough cancer pain development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Iniparib — NCT01097018 | Failed to demonstrate efficacy in phase 3 (breast cancer); no BTcP benefit established | Promising early-phase signals did not translate to phase 3 efficacy in cancer-related endpoints |
| Perifosine — NCT01002248 | Did not meet primary endpoints in phase 3 (colorectal cancer) | Reflects high oncology attrition; indirect relevance to cancer-pain therapeutics |
Choosing the right endpoint
Primary endpoints that matter in breakthrough cancer pain trials
- Pain intensity reduction (SPID) — Summed pain intensity difference over 30-60 min is the core efficacy measure for rapid-onset agents
- Onset of relief — Time to meaningful relief (often within 5-15 min) is decisive for acute episodes
- Duration of pain relief — Indicates sustained efficacy and dosing frequency; hard to capture with recall bias
- Side effects / tolerability — Respiratory depression, sedation, and constipation drive adherence and safety monitoring
- Patient-reported outcomes / satisfaction — Real-time pain diaries and ePRO tools reduce recall error in the outpatient setting
How iNGENū runs breakthrough cancer pain trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Breakthrough Cancer Pain clinical trials — FAQs
Are there currently FDA-approved TIRF drugs for breakthrough cancer pain?
Why are BTcP trials difficult to design?
What endpoint best captures rapid-onset efficacy?
Ready to discuss your breakthrough cancer pain trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal